Becton Dickinson SG&A Expenses 2010-2024 | BDX
Becton Dickinson annual/quarterly sg&a expenses history and growth rate from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
- Becton Dickinson sg&a expenses for the quarter ending June 30, 2024 were $1.196B, a 0.5% increase year-over-year.
- Becton Dickinson sg&a expenses for the twelve months ending June 30, 2024 were $4.739B, a 0.55% decline year-over-year.
- Becton Dickinson annual sg&a expenses for 2023 were $4.719B, a 0.21% increase from 2022.
- Becton Dickinson annual sg&a expenses for 2022 were $4.709B, a 0.21% decline from 2021.
- Becton Dickinson annual sg&a expenses for 2021 were $4.719B, a 12.76% increase from 2020.
Becton Dickinson Annual SG&A Expenses
(Millions of US $) |
| 2023 |
$4,719 |
| 2022 |
$4,709 |
| 2021 |
$4,719 |
| 2020 |
$4,185 |
| 2019 |
$4,332 |
| 2018 |
$4,016 |
| 2017 |
$2,909 |
| 2016 |
$3,005 |
| 2015 |
$2,563 |
| 2014 |
$2,145 |
| 2013 |
$2,422 |
| 2012 |
$1,923 |
| 2011 |
$1,824 |
| 2010 |
$1,691 |
| 2009 |
$1,681 |
Becton Dickinson Quarterly SG&A Expenses
(Millions of US $) |
| 2024-06-30 |
$1,196 |
| 2024-03-31 |
$1,193 |
| 2023-12-31 |
$1,213 |
| 2023-09-30 |
$1,137 |
| 2023-06-30 |
$1,190 |
| 2023-03-31 |
$1,205 |
| 2022-12-31 |
$1,187 |
| 2022-09-30 |
$1,183 |
| 2022-06-30 |
$1,149 |
| 2022-03-31 |
$1,192 |
| 2021-12-31 |
$1,185 |
| 2021-09-30 |
$1,222 |
| 2021-06-30 |
$1,200 |
| 2021-03-31 |
$1,148 |
| 2020-12-31 |
$1,149 |
| 2020-09-30 |
$1,059 |
| 2020-06-30 |
$980 |
| 2020-03-31 |
$1,025 |
| 2019-12-31 |
$1,121 |
| 2019-09-30 |
$1,094 |
| 2019-06-30 |
$1,076 |
| 2019-03-31 |
$1,089 |
| 2018-12-31 |
$1,073 |
| 2018-09-30 |
$1,101 |
| 2018-06-30 |
$1,086 |
| 2018-03-31 |
$1,056 |
| 2017-12-31 |
$773 |
| 2017-09-30 |
$757 |
| 2017-06-30 |
$719 |
| 2017-03-31 |
$724 |
| 2016-12-31 |
$709 |
| 2016-09-30 |
$797 |
| 2016-06-30 |
$728 |
| 2016-03-31 |
$732 |
| 2015-12-31 |
$748 |
| 2015-09-30 |
$757 |
| 2015-06-30 |
$751 |
| 2015-03-31 |
$511 |
| 2014-12-31 |
$544 |
| 2014-09-30 |
$561 |
| 2014-06-30 |
$528 |
| 2014-03-31 |
$525 |
| 2013-12-31 |
$531 |
| 2013-09-30 |
$877 |
| 2013-06-30 |
$534 |
| 2013-03-31 |
$515 |
| 2012-12-31 |
$496 |
| 2012-09-30 |
$484 |
| 2012-06-30 |
$469 |
| 2012-03-31 |
$488 |
| 2011-12-31 |
$482 |
| 2011-09-30 |
$466 |
| 2011-06-30 |
$468 |
| 2011-03-31 |
$442 |
| 2010-12-31 |
$448 |
| 2010-09-30 |
$408 |
| 2010-06-30 |
$416 |
| 2010-03-31 |
$421 |
| 2009-12-31 |
$446 |
| 2009-09-30 |
$408 |
| 2009-06-30 |
$430 |
| 2009-03-31 |
$436 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$67.812B |
$20.178B |
|
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
|
